Oncology The following graph shows the comparitive spending on oncology products between 2010 and 2012 in the US, the EU, Japan, BRICs and other countries.
development Glenmark’s country manager for Argentina discusses Argentina’s development expertise and how companies like Glenmark can capitalize on it through partnerships and collaborations. How did you become part of Glenmark, and what was your main objective when you took the helm in Argentina? I joined Glenmark five years ago as…
Internationalization José Fernández, president of the Zeltia Group, outlines the company’s strategy for developing oncology drugs through marine-based organisms with the group’s subsidiary PharmaMar. With €550 [SG1] million invested in research and development in total, Zeltia was finally able to commercialize a novel product. Would you say that this investment was worth…
Cardiology The president & CEO of CQDM discusses her vision of how CQDM’s activities can have a direct impact on the development of safer and more efficient drugs, and how to bring CQDM to a more globally competitive level. You were appointed as CEO of CQDM about ten months ago. What…
See our Cookie Privacy Policy Here
